Statistical Analysis Plan for Day 28 analyses for CEPI fourth dose Australia study

Statistical analysis plan for 28 day analysis for: a randomised controlled trial to assess the immunogenicity, safety and reactogenicity of a bivalent mRNA Moderna COVID-19 vaccine or a protein-based Novavax COVID-19 vaccine given as a fourth dose in healthy adults in Australia.

Version 1.0, dated 19th March 2024